Browsing Tag
Foresee Pharmaceuticals
4 posts
Foresee Pharmaceuticals licenses MMP-12 pipeline to Primevera in $594m reset to double down on CAMCEVI and injectables
Foresee signs $594 million licensing deal with Primevera Therapeutics to exit MMP-12 R&D and focus on CAMCEVI injectables. Read what this signals for biotech strategy.
Foresee Pharmaceuticals gains third DSMB endorsement for Casppian Phase 3 study, strengthening confidence in long-acting Leuprolide formulation
The latest safety review supports Foresee Pharmaceuticals’ continued progress in developing a long-acting leuprolide injectable emulsion for pediatric…
Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat
Foresee Pharmaceuticals (TPEx: 6576) has reported successful preliminary results from its Phase 1 clinical trial of linvemastat (FP-020),…
Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS
Foresee Pharmaceuticals has started patient dosing in a phase 2/3 trial of FP-025 in adults having severe to…